Nagase Hiroshi, Kutsumura Noriki
International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan.
Arch Pharm (Weinheim). 2015 Jun;348(6):375-89. doi: 10.1002/ardp.201500031. Epub 2015 May 12.
We designed and synthesized novel triplet molecules with 1,3,5-trioxazatriquinane skeletons. One class comprises double-capped triplets with a morphinan skeleton; the other class comprises simple phenol derivatives with phenethylamine moieties. One compound with m-phenolic hydroxyl group, called SYK-146, is a highly selective, potent agonist for the κ receptor, with activity nearly equivalent to that of U-50488H. The o-phenolic isomer of SYK-146, called SYK-524, showed potent but non-selective agonistic activity for the opioid receptors. We also added several simple phenol derivatives to a library of compounds that target opioid receptors, and they showed high hit rates for the receptor. This library might also be expected to show high hit rates for other receptors.
我们设计并合成了具有1,3,5-三恶唑并三喹烷骨架的新型三线态分子。一类包括具有吗啡喃骨架的双封端三线态分子;另一类包括具有苯乙胺部分的简单酚类衍生物。一种具有间位酚羟基的化合物,称为SYK-146,是一种对κ受体具有高度选择性、强效的激动剂,其活性几乎与U-50488H相当。SYK-146的邻位酚异构体,称为SYK-524,对阿片受体表现出强效但非选择性的激动活性。我们还将几种简单的酚类衍生物添加到靶向阿片受体的化合物库中,它们对该受体显示出高命中率。这个化合物库可能也有望对其他受体显示出高命中率。